Search results
Results from the WOW.Com Content Network
In 2012, Advair was part of a larger civil settlement agreement between GlaxoSmithKline (GSK) and the United States, in which GSK agreed to pay $1.043 billion; the United States said that GSK promoted off-label uses of Advair and paid kickbacks to healthcare professionals to sell this drug, among others.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
In January 2019, the FDA announced its approval of the company's Wixela Inhub, the first approved generic version of GlaxoSmithKline's Advair Diskus. [ 81 ] Merger with Pfizer's off-patent drug business and name change to Viatris
The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...
Download QR code; Print/export ... Advair Small molecule ... Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013
For premium support please call: 800-290-4726 more ways to reach us
Prasco has licensed generic versions of a variety of brand-name prescription drugs, including the antihistamine Allegra, [3] [4] progestin Cyclessa (used in combined oral contraceptive pills), [5] the insomnia medication Ambien, GERD medication Protonix, Advair Diskus, and others allowing them to be the leading authorized generic company with ...
In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent.